E-Z-EM ponders IPO for AngioDynamics subsidiary
This article was originally published in Clinica
Gastrointestinal contrast media specialist E-Z-EM, of Lake Success, New York, is considering a spin-off or initial public offering of its wholly owned subsidiary, AngioDynamics. "The view is that the IPO market, which has been weak for a number of years, is turning, and that activity is expected from the beginning of 2004," E-Z-EM chief financial officer Dennis Curtin told Clinica Direct.
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.